InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Zhengye Biotechnology Holding Ltd

ZYBT Clue Score38
China CIK 0001975641
$1.69 -2.31% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.69 −40.91% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 7 Jan 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Revenue260.3Operating income65.8Net income46.7EPS, diluted1.02Fiscal year 2023Revenue211.7 −18.7%Operating income45.0Net income31.5 −32.7%EPS, diluted0.69 −32.4%Fiscal year 2024Revenue186.4 −12.0%Operating income16.4Net income11.3 −64.0%EPS, diluted0.25 −63.8%Fiscal year 2025Revenue116.4 −37.6%Operating income−70.5Net income−69.8 −717.0%
FY2022FY2023FY2024FY2025
Revenue 260.3 211.7 186.4 116.4
Growth −18.7% −12.0% −37.6%
Operating income 65.8 45.0 16.4 −70.5
Net income 46.7 31.5 11.3 −69.8
Growth −32.7% −64.0% −717.0%
EPS, diluted 1.02 0.69 0.25 n/a
Growth −32.4% −63.8%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2022Gross margin56.8%Operating margin25.3%Net margin18.0%Free cash flow margin−3.8%Fiscal year 2023Gross margin55.5%Operating margin21.3%Net margin14.9%Free cash flow margin19.3%Fiscal year 2024Gross margin49.0%Operating margin8.8%Net margin6.1%Free cash flow margin14.7%Fiscal year 2025Gross margin20.5%Operating margin−60.6%Net margin−60.0%Free cash flow margin10.6%
FY2022FY2023FY2024FY2025
Gross margin 56.8% 55.5% 49.0% 20.5%
Operating margin 25.3% 21.3% 8.8% −60.6%
Net margin 18.0% 14.9% 6.1% −60.0%
Free cash flow margin −3.8% 19.3% 14.7% 10.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow17.3Capital expenditure−27.3Free cash flow−10.0Dividends paid−21.4Fiscal year 2023Operating cash flow48.2Capital expenditure−7.4Free cash flow40.8Dividends paid−39.5Fiscal year 2024Operating cash flow41.0Capital expenditure−13.6Free cash flow27.5 −32.7%Dividends paid−16.0Fiscal year 2025Operating cash flow13.3Capital expenditure−1.0Free cash flow12.3 −55.1%
FY2022FY2023FY2024FY2025
Operating cash flow 17.3 48.2 41.0 13.3
Capital expenditure −27.3 −7.4 −13.6 −1.0
Free cash flow −10.0 40.8 27.5 12.3
Growth −32.7% −55.1%
Dividends paid −21.4 −39.5 −16.0 n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2022Cash9.7Shareholders’ equity356.9Fiscal year 2023Cash15.1Total debt10.0Net cash (debt)5.1Shareholders’ equity272.9Debt to equity0.04Fiscal year 2024Cash18.6Total debt12.0Net cash (debt)6.6Shareholders’ equity284.0Debt to equity0.04Fiscal year 2025Cash50.3Total debt10.3Net cash (debt)40.1Shareholders’ equity249.8Debt to equity0.04
FY2022FY2023FY2024FY2025
Cash 9.7 15.1 18.6 50.3
Total debt n/a 10.0 12.0 10.3
Net cash (debt) n/a 5.1 6.6 40.1
Shareholders’ equity 356.9 272.9 284.0 249.8
Debt to equity n/a 0.04 0.04 0.04

In millions of CNY, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
56.8% 55.5% 49.0% 20.5%
25.3% 21.3% 8.8% −60.6%
24.6% 20.7% 7.7% −61.8%
18.0% 14.9% 6.1% −60.0%
−3.8% 19.3% 14.7% 10.6%
Spending
5.2% 5.6% 6.9% 15.5%
9.3% 11.1% 12.1% 26.6%
10.5% 3.5% 7.3% 0.9%
12.8% 14.3% 6.4% n/a
Returns
13.1% 11.5% 4.0% −27.9%
n/a 6.3% 2.3% −16.0%
Balance and payout
n/a 0.04 0.04 0.04
n/a 32.1% 28.5% 29.7%
45.8% 125.4% 141.7% n/a
n/a 96.7% 58.4% n/a

Shown in CNY as filed; the screener converts to dollars.